कृपया अन्य खोज का प्रयास करें
KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Lyfuna for cough treatment; Desalex, an antiallergic agent; Beova, Uritos, and Imidafenacin KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex and Mometasone KYORIN, which are used as allergic rhinitis therapeutic agents; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug. It also provides Mucodyne, a mucoregulating drug; Montelukast KM, a drug for the treatment of bronchial asthma and allergic rhinitis; GeneSoC, a real-time PCR system; Rubysta, a disinfectant cleaner; Milton, a disinfectant; over-the-counter drugs; prescription medicines and quasi-drugs, diagnostics, and industrial chemicals; and reagents, intermediates, and other products. In addition, the company offers subcontracted drug manufacturing services. Further, it is involved in the discovery and evaluation of candidate compounds; and research and analysis of other companies’ technologies and collection of information concerning clinical trial. The company was formerly known as KYORIN Holdings, Inc. KYORIN Pharmaceutical Co., Ltd. was founded in 1923 and is headquartered in Tokyo, Japan.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Kenji Akutsu | 67 | 2016 | Senior Corporate Auditor |
Tomiharu Matsumoto | 70 | 2018 | Chairman of Corporate Auditors |
Michiro Onota | 63 | 2017 | Executive Director & CMO |
Takao Yamaguchi | 69 | - | Outside Member of Audit & Supervisory Board |
Noriyuki Shikanai | 75 | 2013 | Independent Outside Director |
Hiromi Watanabe | 76 | 2019 | Independent Outside Director |
Kensuke Morita | 57 | 2022 | Outside Audit & Supervisory Board Member |
Ken Shigematsu | 75 | 2017 | Independent Outside Director |
Yukio Ikemura | 65 | 2022 | Outside Audit & Supervisory Board Member |
Hiroshi Hashizume | - | 2018 | Executive Officer, President & Representative Director of Kyorin Rimedio Co., Ltd. |
Yutaka Ogihara | 57 | 2011 | President, CEO & Representative Director |
Yasuji Kurose | - | 2024 | CFO, CStO, Director of Corporate Planning & Executive Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है